1. Home
  2. News
  3. Shield Therapeutics PLC
  4. Shield Therapeutics: Interim results for the six months ended 30 June 2025
More Shield Therapeutics PLC news
Shield Therapeutics PLCLSE: STX

Shield Therapeutics: Interim results for the six months ended 30 June 2025

Aug 21, 2025 at 7:08 AM EDT · Issued by Shield Therapeutics PLC

On 6ix: 6ix.com/news/shield-therapeutics-interim-results-for-the-six-months-ended-30-june-2025

Watch Shield Therapeutics' latest callShield Therapeutics (LSE:STX) — Q4 2025 Trading Update · Replay · Jan 22↗
Interim results for the six months ended 30 June 2025
Interim results for the six months ended 30 June 2025

Back to News

Shield Therapeutics PLC on 6ix

Story so far

  • Annual Report and Accounts for the year ended 2024Apr 25, 2025
  • Interim resultsSep 4, 2024
  • Notice of interim resultsAug 14, 2024

Earlier from Shield Therapeutics

  • Q2 2025 Trading UpdateJul 23, 2025
  • Result of AGMMay 22, 2025
  • Annual Report and Accounts for the year ended 2024Apr 25, 2025
  • Audited results for the year ended 31 Dec 2024Apr 24, 2025
  • Licence Agreement in Japan for ACCRUFeR®Apr 22, 2025

Later from Shield Therapeutics

  • Data published -European Journal of Heart FailureAug 27, 2025
  • Interim results for the six months ended 30 Jun 25Sep 3, 2025
  • ACCRUFeR® assigned Priority Review in US by FDASep 4, 2025
  • £1.5 million placing supporting growth of ACCRUFeRSep 15, 2025
  • Positive efficacy and tolerance in pediatric trialOct 1, 2025
All Shield Therapeutics news releases↗

Follow Shield Therapeutics into a list and get an email when it puts out news.

Follow Shield Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer